IWP's Underlying Holdings Could Mean 11% Gain Potential
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 22 2025
0mins
Source: NASDAQ.COM
ETF Analysis: The iShares Russell Mid-Cap Growth ETF (IWP) has an implied analyst target price of $144.41, indicating a potential upside of 10.59% from its recent trading price of $130.58.
Stock Performance Insights: Notable underlying holdings such as Ionis Pharmaceuticals, Veeva Systems, and Ares Management show significant upside potential based on analyst targets, raising questions about the validity of these projections amidst market conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VEEV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VEEV
Wall Street analysts forecast VEEV stock price to rise
23 Analyst Rating
16 Buy
6 Hold
1 Sell
Moderate Buy
Current: 158.540
Low
222.00
Averages
317.10
High
380.00
Current: 158.540
Low
222.00
Averages
317.10
High
380.00
About VEEV
Veeva Systems Inc. is a provider of cloud solutions for the global life sciences industry. It offers span cloud software, data and business consulting and is designed to meet the needs of its customers and strategic business functions from research and development (R&D) through commercialization. Its product categories include Veeva Development Cloud, Veeva Quality Cloud, Veeva Commercial Cloud and Veeva Data Cloud. Veeva Development Cloud includes application suites for the clinical, regulatory, and safety functions of life sciences companies, all built on its Veeva Vault platform. Veeva Quality Cloud unifies applications, processes and partners across content management, training, quality management, assurance and control lab solutions on the Veeva Vault platform. Veeva Commercial Cloud is a product category comprised of software and analytics solutions. It owns Ostro, a brand engagement platform for life sciences that gives an artificial intelligence (AI)-driven chat experience.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Merck KGaA Commits to Global Partnership with Veeva Vault CRM
- Global Partnership Agreement: Merck KGaA has committed to a global partnership with Veeva Systems, adopting Veeva Vault CRM to enhance its digital transformation, which is expected to significantly improve operational efficiency and customer service through better data connectivity and consistency.
- Digital Transformation Strategy: By integrating Veeva Vault, Merck KGaA's health division can achieve seamless data flow across different functions, thereby enhancing overall business flexibility to adapt to changing market demands.
- AI-Driven Efficiency Gains: The AI capabilities of Veeva Vault CRM will provide Merck KGaA with multiple intelligent agents aimed at boosting commercial efficiency and effectiveness, helping the company maintain a competitive edge in the fast-paced biopharmaceutical market.
- Customer-Centric Innovation: The implementation of Veeva Vault CRM will enable Merck KGaA to better meet customer needs by enhancing customer satisfaction and market share through integrated management capabilities and customer-oriented workflows.
See More
Veeva Launches Falcon Platform to Enhance Drug Development Efficiency
- Platform Launch: Veeva Systems has announced the launch of the Falcon platform, designed to enhance efficiency in drug development processes through standardized agents and workflows, which is expected to significantly reduce development costs for biopharmaceutical companies.
- Function Integration: Falcon seamlessly integrates with Veeva's clinical, regulatory, and safety applications, enabling faster document receipt and quality control processes, thereby improving compliance and accelerating time-to-market for drugs.
- Market Demand Response: Veeva anticipates that Falcon will be available to early users in November 2026, addressing the urgent need for automation and efficient processes in the biopharmaceutical industry, further solidifying its market leadership.
- Strategic Significance: As part of Veeva AI solutions, Falcon represents the company's commitment to innovation in drug development, aiming to drive overall industry efficiency through technological advancements.
See More
Veeva Launches Falcon Platform to Enhance Drug Development Efficiency
- Platform Innovation: Veeva has launched the Falcon platform, integrating AI agents and ready-to-use agents aimed at enhancing drug development efficiency in the biopharma sector, which is expected to significantly reduce development costs and accelerate timelines.
- Application Compatibility: Falcon is compatible with Veeva Development Cloud's clinical, regulatory, and safety applications, ensuring that biopharma companies can maintain compliance at all stages, thereby enhancing overall operational efficiency.
- Market Demand Response: The initial application areas of Falcon include document receipt and quality control for trial master files, as well as compliance communication with health regulatory authorities, directly addressing the market's urgent need for faster and more efficient drug development.
- Commitment to Customer Collaboration: Veeva CEO Peter Gassner stated that the launch of Falcon represents a significant initiative in collaboration with clients, aimed at leveraging technological innovation to help the industry reduce costs and accelerate the drug approval process.
See More
Teva Expands Strategic Partnership with Veeva
- Strategic Partnership Expansion: Teva Pharmaceuticals has committed to implementing Veeva Vault CRM globally, aiming to enhance customer interaction and improve commercial execution, thereby solidifying its strategic partnership with Veeva.
- Technological Foundation Enhancement: Vault CRM will provide Teva with the necessary technological foundation to support innovations in neuroscience and immunology, ensuring its competitiveness in the complex generics and biosimilars markets.
- Commitment to Customer Success: Teva and Veeva are jointly committed to customer success, with the implementation of Vault CRM enabling Teva to generate commercial evidence more effectively, enhancing market responsiveness and increasing customer satisfaction.
- Industry Leadership Position: Veeva, as a leading cloud platform in the life sciences sector serving over 1,500 clients, will further solidify its leadership position in the global pharmaceutical industry through this collaboration, driving long-term growth for both parties.
See More
Veeva Launches Falcon Platform to Enhance Drug Development Efficiency
- Platform Innovation: Veeva Systems has launched the Falcon platform, designed to reduce development costs and increase speed for biopharma companies by integrating with Veeva Development Cloud applications, which is expected to have a profound impact on the industry.
- Focus Areas: The initial applications of Falcon concentrate on critical areas such as trial master file document intake, quality control, regulatory correspondence, and safety case triage, aiming to enhance compliance and efficiency.
- Market Outlook: Falcon is set for early adopter availability in November 2026, as part of Veeva AI, marking a significant advancement in the company's industry-specific AI solutions, which may attract more customers.
- Company Vision: Veeva is committed to collaborating with customers through the Falcon platform to drive down costs and increase speed in drug development, further solidifying its leadership position in the life sciences sector.
See More
Veeva Launches Falcon Platform to Enhance Drug Development Efficiency
- Platform Innovation: Veeva Systems has launched the Falcon platform, designed to reduce development costs and increase speed for biopharma companies by integrating with Veeva Development Cloud applications, marking a significant advancement in the realm of agentic labor.
- Focus Areas: The initial applications of Falcon concentrate on trial master file document intake, quality control, regulatory health authority correspondence, and safety case triage and intake, which are expected to significantly enhance the efficiency of these critical processes.
- Customer Collaboration: Veeva's founder and CEO, Peter Gassner, stated that Falcon represents a major initiative to partner with customers, aiming to help the industry lower drug development costs and accelerate processes, reflecting the company's commitment to customer success.
- Future Outlook: Falcon is set for early adopter availability in November 2026 and is part of Veeva AI, further advancing industry-specific AI solutions, indicating Veeva's ongoing innovation in the life sciences sector.
See More
Merck KGaA Commits to Global Partnership with Veeva Vault CRM
- Global Partnership Agreement: Merck KGaA has committed to a global partnership with Veeva Systems, adopting Veeva Vault CRM to enhance its digital transformation, which is expected to significantly improve operational efficiency and customer service through better data connectivity and consistency.
- Digital Transformation Strategy: By integrating Veeva Vault, Merck KGaA's health division can achieve seamless data flow across different functions, thereby enhancing overall business flexibility to adapt to changing market demands.
- AI-Driven Efficiency Gains: The AI capabilities of Veeva Vault CRM will provide Merck KGaA with multiple intelligent agents aimed at boosting commercial efficiency and effectiveness, helping the company maintain a competitive edge in the fast-paced biopharmaceutical market.
- Customer-Centric Innovation: The implementation of Veeva Vault CRM will enable Merck KGaA to better meet customer needs by enhancing customer satisfaction and market share through integrated management capabilities and customer-oriented workflows.
See More
Veeva Launches Falcon Platform to Enhance Drug Development Efficiency
- Platform Launch: Veeva Systems has announced the launch of the Falcon platform, designed to enhance efficiency in drug development processes through standardized agents and workflows, which is expected to significantly reduce development costs for biopharmaceutical companies.
- Function Integration: Falcon seamlessly integrates with Veeva's clinical, regulatory, and safety applications, enabling faster document receipt and quality control processes, thereby improving compliance and accelerating time-to-market for drugs.
- Market Demand Response: Veeva anticipates that Falcon will be available to early users in November 2026, addressing the urgent need for automation and efficient processes in the biopharmaceutical industry, further solidifying its market leadership.
- Strategic Significance: As part of Veeva AI solutions, Falcon represents the company's commitment to innovation in drug development, aiming to drive overall industry efficiency through technological advancements.
See More
Veeva Launches Falcon Platform to Enhance Drug Development Efficiency
- Platform Innovation: Veeva has launched the Falcon platform, integrating AI agents and ready-to-use agents aimed at enhancing drug development efficiency in the biopharma sector, which is expected to significantly reduce development costs and accelerate timelines.
- Application Compatibility: Falcon is compatible with Veeva Development Cloud's clinical, regulatory, and safety applications, ensuring that biopharma companies can maintain compliance at all stages, thereby enhancing overall operational efficiency.
- Market Demand Response: The initial application areas of Falcon include document receipt and quality control for trial master files, as well as compliance communication with health regulatory authorities, directly addressing the market's urgent need for faster and more efficient drug development.
- Commitment to Customer Collaboration: Veeva CEO Peter Gassner stated that the launch of Falcon represents a significant initiative in collaboration with clients, aimed at leveraging technological innovation to help the industry reduce costs and accelerate the drug approval process.
See More
Teva Expands Strategic Partnership with Veeva
- Strategic Partnership Expansion: Teva Pharmaceuticals has committed to implementing Veeva Vault CRM globally, aiming to enhance customer interaction and improve commercial execution, thereby solidifying its strategic partnership with Veeva.
- Technological Foundation Enhancement: Vault CRM will provide Teva with the necessary technological foundation to support innovations in neuroscience and immunology, ensuring its competitiveness in the complex generics and biosimilars markets.
- Commitment to Customer Success: Teva and Veeva are jointly committed to customer success, with the implementation of Vault CRM enabling Teva to generate commercial evidence more effectively, enhancing market responsiveness and increasing customer satisfaction.
- Industry Leadership Position: Veeva, as a leading cloud platform in the life sciences sector serving over 1,500 clients, will further solidify its leadership position in the global pharmaceutical industry through this collaboration, driving long-term growth for both parties.
See More
Veeva Launches Falcon Platform to Enhance Drug Development Efficiency
- Platform Innovation: Veeva Systems has launched the Falcon platform, designed to reduce development costs and increase speed for biopharma companies by integrating with Veeva Development Cloud applications, which is expected to have a profound impact on the industry.
- Focus Areas: The initial applications of Falcon concentrate on critical areas such as trial master file document intake, quality control, regulatory correspondence, and safety case triage, aiming to enhance compliance and efficiency.
- Market Outlook: Falcon is set for early adopter availability in November 2026, as part of Veeva AI, marking a significant advancement in the company's industry-specific AI solutions, which may attract more customers.
- Company Vision: Veeva is committed to collaborating with customers through the Falcon platform to drive down costs and increase speed in drug development, further solidifying its leadership position in the life sciences sector.
See More
Veeva Launches Falcon Platform to Enhance Drug Development Efficiency
- Platform Innovation: Veeva Systems has launched the Falcon platform, designed to reduce development costs and increase speed for biopharma companies by integrating with Veeva Development Cloud applications, marking a significant advancement in the realm of agentic labor.
- Focus Areas: The initial applications of Falcon concentrate on trial master file document intake, quality control, regulatory health authority correspondence, and safety case triage and intake, which are expected to significantly enhance the efficiency of these critical processes.
- Customer Collaboration: Veeva's founder and CEO, Peter Gassner, stated that Falcon represents a major initiative to partner with customers, aiming to help the industry lower drug development costs and accelerate processes, reflecting the company's commitment to customer success.
- Future Outlook: Falcon is set for early adopter availability in November 2026 and is part of Veeva AI, further advancing industry-specific AI solutions, indicating Veeva's ongoing innovation in the life sciences sector.
See More
